Paid Clinical Trials and Focus Groups by Category |
|
|
|
Condition: Prostate Cancer
Interventions: Drug: ABT-888; Drug: temozolomide
Sponsor: Abbott
Not yet recruiting - verified February 2010
Condition: Prostate Cancer
Interventions: Drug: TAK-700; Drug: Docetaxel; Drug: Prednisone
Sponsor: Millennium Pharmaceuticals, Inc.
Recruiting - verified March 2010
Condition: Prostate Cancer
Interventions: Drug: Testosterone; Drug: Etoposide
Sponsor: Sidney Kimmel Comprehensive Cancer Center
Recruiting - verified March 2010
Condition: Prostate Cancer
Intervention: Dietary Supplement: Olive Oil
Sponsors: Brown University; The Miriam Hospital
Recruiting - verified October 2009
Condition: Prostate Cancer
Interventions: Drug: temsirolimus; Biological: bevacizumab; Genetic: polymorphism analysis; Other: laboratory biomarker analysis
Sponsor: Case Comprehensive Cancer Center
Recruiting - verified March 2010
Conditions: Bone Cancer; Bone Metastases; Pain
Intervention: Device: ExAblate 2100
Sponsor: InSightec
Not yet recruiting - verified March 2010
Condition: Prostatic Neoplasms
Intervention: Drug: Ascorbic Acid (Vitamin C)
Sponsors: Copenhagen University Hospital at Herlev; Rigshospitalet, Denmark; University of Copenhagen
Not yet recruiting - verified March 2010
Condition: Prostate Cancer
Intervention: Device: CONTINUUM™
Sponsor: American Medical Systems
Recruiting - verified March 2010
Condition: Prostate Cancer
Interventions: Drug: ixabepilone; Procedure: adjuvant therapy; Radiation: intensity-modulated radiation therapy
Sponsors: Simmons Cancer Center; National Cancer Institute (NCI)
Not yet recruiting - verified February 2010
Conditions: Advanced Prostate Cancer; Lower Urinary Tract Symptoms
Intervention: Drug: Leuprolide acetate Depot Susp. 11,25 mg (Poland), 3,75 mg (Ukraine)
Sponsors: Abbott; Fraktal; TFS Trial Form Support
Active, not recruiting - verified February 2010
Condition: Prostatic Neoplasm
Intervention: Drug: leuprolide (Lucrin/Lucrin-Tri-depot)
Sponsor: Abbott
Active, not recruiting - verified March 2010
Conditions: Castrate-Resistant Prostate Cancer; Hormone Refractory Prostate Cancer
Interventions: Drug: custirsen sodium; Drug: Isotonic, 0.9% sodium chloride
Sponsors: OncoGenex Technologies; Teva Pharmaceuticals USA
Not yet recruiting - verified March 2010
Condition: Prostatic Neoplasms
Intervention:
Sponsor: Sanofi-Aventis
Recruiting - verified February 2010
Condition: Prostate Cancer
Interventions: Drug: HDAC inhibitor SB939; Other: laboratory biomarker analysis
Sponsor: NCIC Clinical Trials Group
Recruiting - verified February 2010
Condition: Prostate Cancer
Interventions: Drug: Neoadjuvant Hormonal Therapy; Drug: Docetaxel
Sponsor: M.D. Anderson Cancer Center
Active, not recruiting - verified February 2010
Condition: Bone-Metastatic, Castration-Resistant Prostate Cancer
Intervention: Drug: KX2-391
Sponsor: Kinex Pharmaceuticals, LLC
Recruiting - verified March 2010
Condition: Prostate Cancer
Intervention:
Sponsor: University of Florida
Recruiting - verified February 2010
Condition: Prostate Cancer
Intervention: Drug: Degarelix
Sponsors: Ferring Pharmaceuticals; Ferring Pharmaceuticals Korea, Ltd.
Not yet recruiting - verified February 2010
Conditions: Metabolic Syndrome; Hypercholesterolemia
Intervention: Drug: Metformin
Sponsor: Sydney West Area Health Service
Recruiting - verified February 2010
Conditions: Depressive Disorder; Cancer
Interventions: Drug: Regular bupropion use; Drug: Regular SSRI (Selective serotonin reuptake inhibitors) use; Drug: Regular use of any other antidepressant; Drug: Regular TCA (Tricyclic antidepressants) use
Sponsor: GlaxoSmithKline
Active, not recruiting - verified February 2010
Condition: Prostate Cancer
Interventions: Drug: Ipilimumab; Drug: Placebo
Sponsor: Bristol-Myers Squibb
Not yet recruiting - verified January 2010
Condition: Prostate Cancer
Interventions: Drug: carboplatin; Drug: everolimus; Drug: prednisone; Other: laboratory biomarker analysis; Other: pharmacological study
Sponsors: Barbara Ann Karmanos Cancer Institute; National Cancer Institute (NCI)
Not yet recruiting - verified February 2010
Conditions: Ovarian; Breast; Prostate; Pancreatic; Advanced Tumours
Intervention: Drug: olaparib
Sponsor: AstraZeneca
Recruiting - verified March 2010
Condition: Prostate Cancer
Intervention: Drug: TAK-700
Sponsor: Millennium Pharmaceuticals, Inc.
Not yet recruiting - verified February 2010
Condition: Prostate Cancer
Interventions: Biological: cixutumumab; Drug: temsirolimus; Other: laboratory biomarker analysis
Sponsors: Memorial Sloan-Kettering Cancer Center; National Cancer Institute (NCI)
Recruiting - verified January 2010
Condition: Prostatic Neoplasms
Intervention: Other: PCA3 Assay
Sponsor: Gen-Probe, Incorporated
Recruiting - verified March 2010
Condition: Erectile Dysfunction
Interventions: Drug: Tadalafil; Drug: Placebo
Sponsor: Eli Lilly and Company
Recruiting - verified February 2010
Conditions: Prostate Cancer; Obesity
Intervention:
Sponsor: AstraZeneca
Recruiting - verified March 2010
Condition: Metastatic Castration-Resistant Prostate Cancer
Intervention: Drug: dextromethorphan hydrobromide or theophylline
Sponsor: Cougar Biotechnology, Inc.
Recruiting - verified February 2010
Conditions: Hereditary Prostate Cancer; Prostate Cancer
Interventions: Genetic: DNA analysis; Genetic: polymorphism analysis; Other: laboratory biomarker analysis; Other: medical chart review; Other: questionnaire administration; Procedure: evaluation of cancer risk factors; Procedure: study of high risk factors
Sponsor: Department of Veterans Affairs
Recruiting - verified November 2009
Condition: Prostatic Neoplasms
Intervention: Drug: Temsirolimus
Sponsors: Stanford University; National Comprehensive Cancer Network; Wyeth; American Society of Clinical Oncology
Recruiting - verified February 2010
Condition: Prostate Cancer
Intervention: Procedure: Prostatectomy
Sponsor: Roswell Park Cancer Institute
Not yet recruiting - verified March 2010
Conditions: Prostatic Neoplasms; Cancer of Prostate; Prostate Cancer; Prostate Neoplasms
Interventions: Procedure: Laparoscopic Radical Prostatectomy (without a simulator) - no intervention; Procedure: Laparoscopic Radical Prostatectomy (with a simulator)
Sponsor: Assistance Publique - Hôpitaux de Paris
Recruiting - verified October 2009
Condition: Castrate-Resistant Prostate Cancer
Intervention: Drug: Lenalidomide (CC-5013) 10mg, 15mg, 20mg, 25mg and their respective matching placebo capsules for oral administration
Sponsor: Celgene Corporation
Recruiting - verified March 2010
Condition: Metastatic Prostate Cancer
Intervention:
Sponsor: Fred Hutchinson Cancer Research Center
Recruiting - verified February 2010
Condition: Prostate Cancer
Intervention: Drug: CNTO888
Sponsor: Centocor, Inc.
Recruiting - verified February 2010
Condition: Localized Prostate Cancer
Interventions: Behavioral: PC-PEP - Prostate Cancer Patient Education Program; Behavioral: Usual care
Sponsors: Baylor College of Medicine; American Cancer Society; Michael Debakey Veterans Affairs Medical Center
Recruiting - verified March 2010
Conditions: Breast Cancer; Prostate Cancer
Interventions: Behavioral: group intervention and questionnaires; Behavioral: individual phone intervention and questionnaires
Sponsor: Memorial Sloan-Kettering Cancer Center
Recruiting - verified March 2010
Condition: Castration-Resistant Prostate Cancer
Interventions: Drug: MDV3100; Drug: Placebo
Sponsor: Medivation, Inc.
Recruiting - verified March 2010
Condition: Diagnostic Imaging
Interventions: Drug: BAY 86-4367; Drug: BAY 86-4367
Sponsor: Bayer
Recruiting - verified February 2010
Conditions: Colorectal Neoplasms; Lung Neoplasms; Breast Neoplasms; Prostatic Neoplasms; Sarcoma
Interventions: Drug: figitumumab; Drug: pegvisomant
Sponsor: Pfizer
Recruiting - verified March 2010
Condition: Prostate Cancer
Interventions: Biological: androgen ablation + dendritic cell vaccine; Biological: androgen ablation plus dendritic cell vaccine
Sponsor: University of Pittsburgh
Recruiting - verified March 2010
Condition: Prostate Cancer
Interventions: Drug: TOK-001; Drug: TOK-001; Drug: TOK-001
Sponsor: Tokai Pharmaceuticals
Recruiting - verified February 2010
Conditions: Bone Metastases in Men With Hormone-Refractory Prostate Cancer; Bone Metastases in Subjects With Advanced Breast Cancer; Bone Metastases in Subjects With Advanced Cancer or Multiple Myeloma
Intervention: Drug: amg 162
Sponsor: Amgen
Enrolling by invitation - verified March 2010
Conditions: Bladder Cancer; Prostate Cancer; Transitional Cell Cancer of the Renal Pelvis and Ureter; Urethral Cancer
Interventions: Biological: bevacizumab; Drug: cisplatin; Drug: gemcitabine hydrochloride; Drug: placebo administration
Sponsors: Cancer and Leukemia Group B; National Cancer Institute (NCI)
Recruiting - verified March 2010
Conditions: Urinary Incontinence; Prostate Cancer
Intervention: Device: Surgisis Male Sling
Sponsor: Cook
Recruiting - verified February 2010
Condition: Prostate Cancer
Interventions: Drug: bicalutamide; Drug: buserelin; Drug: flutamide; Drug: goserelin; Drug: leuprolide acetate; Drug: triptorelin; Radiation: 3-dimensional conformal radiation therapy; Radiation: intensity-modulated radiation therapy
Sponsors: Radiation Therapy Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Conditions: Solid Tumors; Cancer
Interventions: Drug: XL184; Drug: Placebo; Drug: XL184
Sponsor: Exelixis
Recruiting - verified February 2010
Conditions: Prostate Cancer; Sexual Dysfunction and Infertility
Interventions: Drug: tadalafil; Other: placebo
Sponsors: Radiation Therapy Oncology Group; National Cancer Institute (NCI)
Suspended - verified March 2010
Conditions: Cancer; Cataract; Low Bone Mineral Density; Osteopenia; Osteoporosis; Prostate Cancer
Interventions: Biological: Denosumab; Biological: Placebo
Sponsor: Amgen
Recruiting - verified March 2010
Condition: Prostate Cancer
Interventions: Drug: abiraterone acetate plus leuprolide acetate plus prednisone; Drug: leuprolide acetate
Sponsor: Cougar Biotechnology, Inc.
Recruiting - verified March 2010
Conditions: Breast Cancer; Healthy Volunteer
Intervention:
Sponsor: National Cancer Institute (NCI)
Recruiting - verified April 2009
Condition: Prostate Cancer
Intervention:
Sponsor: University Health Network, Toronto
Active, not recruiting - verified February 2010
Conditions: Metastatic Cancer; Prostate Cancer
Interventions: Other: imaging biomarker analysis; Other: laboratory biomarker analysis; Other: pharmacological study; Procedure: bone scan; Procedure: scintigraphy; Radiation: calcium-41 chloride aqueous solution; Radiation: calcium-46 chloride aqueous solution
Sponsors: University of California, Davis; National Cancer Institute (NCI)
Not yet recruiting - verified March 2010
Condition: Prostate Cancer
Interventions: Drug: Docetaxel; Drug: Prednisone; Drug: 177Lu-J591; Drug: 177Lu-J591; Drug: 177Lu-J591; Drug: 177Lu-J591; Drug: 177Lu-J591
Sponsor: Weill Medical College of Cornell University
Recruiting - verified March 2010
Conditions: Breast Cancer; Glioma; Hepatocellular Cancer; Squamous Cell Lung Cancer; Pancreatic Cancer; Colon Cancer; Prostate Cancer
Intervention: Biological: Autologous Natural Killer / Natural Killer T Cell Immunotherapy
Sponsor: Envita Medical Center, Inc.
Suspended - verified February 2010
Conditions: Impotence; Prostatic Neoplasms
Interventions: Drug: Sildenafil therapy plus post-NSRRP HBO2T; Drug: Sildenafil therapy plus sham post-NSRRP HBO2T
Sponsor: Hartford Hospital
Recruiting - verified March 2010
Condition: Prostate Cancer
Interventions: Procedure: Urodynamics Test; Behavioral: Questionnaire
Sponsor: M.D. Anderson Cancer Center
Active, not recruiting - verified February 2010
Condition: Prostate Cancer
Interventions: Genetic: microarray analysis; Other: laboratory biomarker analysis
Sponsors: Radiation Therapy Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Conditions: Breast Cancer; Colorectal Cancer; Head and Neck Cancer; Lung Cancer; Prostate Cancer
Interventions: Other: laboratory biomarker analysis; Radiation: radiation therapy
Sponsor: Vanderbilt-Ingram Cancer Center
Active, not recruiting - verified February 2010
Condition: Prostate Cancer
Intervention: Drug: Sipuleucel-T
Sponsor: Dendreon
Recruiting - verified March 2010
Condition: Prostate Cancer
Interventions: Drug: Contrast-enhanced ultrasound guided biopsy; Procedure: ultrasound guided systematic biopsy
Sponsors: Bracco Diagnostics, Inc; Bracco Imaging SpA
Recruiting - verified February 2010
Condition: Hypertension
Intervention: Other: Interactive Spaced Education (ISE) --- online education
Sponsor: Department of Veterans Affairs
Not yet recruiting - verified February 2010
Condition: Cancer
Interventions: Other: immunological diagnostic method; Other: physiologic testing
Sponsors: Wake Forest University; National Cancer Institute (NCI)
Recruiting - verified June 2009
Condition: Prostate Cancer
Intervention: Behavioral: QOL Questionnaire
Sponsor: M.D. Anderson Cancer Center
Recruiting - verified March 2010
Conditions: Breast Cancer; Lung Cancer; Metastatic Cancer; Multiple Myeloma and Plasma Cell Neoplasm; Prostate Cancer; Unspecified Adult Solid Tumor, Protocol Specific
Intervention: Procedure: assessment of therapy complications
Sponsors: Southwest Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Condition: Erectile Dysfunction
Interventions: Other: aerobic exercise; Other: wait-list control
Sponsors: Duke University; National Cancer Institute (NCI)
Recruiting - verified February 2010
Conditions: Breast Cancer; Metastatic Cancer; Multiple Myeloma and Plasma Cell Neoplasm; Musculoskeletal Complications; Pain; Prostate Cancer; Urinary Complications
Intervention: Drug: zoledronic acid
Sponsors: Cancer and Leukemia Group B; National Cancer Institute (NCI)
Recruiting - verified March 2010
Conditions: Prostate Cancer; Prostatic Neoplasms
Interventions: Drug: Docetaxel; Drug: Imatinib Mesylate
Sponsors: New York University School of Medicine; Novartis
Active, not recruiting - verified February 2010
Condition: Prostate Cancer
Interventions: Drug: Ipilimumab; Drug: Placebo
Sponsor: Bristol-Myers Squibb
Recruiting - verified January 2010
Condition: Prostate Cancer
Interventions: Drug: Dasatinib; Drug: Leuprolide Acetate (LHRH Analogue); Procedure: Radical Prostatectomy
Sponsors: Hoosier Oncology Group; Bristol-Myers Squibb
Recruiting - verified February 2010
Condition: Prostate Cancer
Interventions: Drug: 177Lu-J591; Drug: Ketoconazole; Drug: Hydrocortisone; Drug: 111In-J591
Sponsor: Weill Medical College of Cornell University
Recruiting - verified March 2010
Condition: Prostate Cancer
Intervention: Device: TRUS probe
Sponsor: Amphia Hospital
Recruiting - verified February 2010
Conditions: Cancer; Fatigue
Intervention:
Sponsor: National Institute of Nursing Research (NINR)
Recruiting - verified December 2009
Conditions: Cancer; Carcinoma; Castrate-Resistant Prostate Cancer; Prostate Cancer; Tumors
Intervention: Drug: Denosumab
Sponsor: Amgen
Recruiting - verified March 2010
Conditions: Breast Neoplasms; Prostatic Neoplasms
Intervention: Biological: Anti-NGF AB
Sponsor: Pfizer
Recruiting - verified March 2010
Condition: Bladder Cancer
Intervention:
Sponsor: University of Colorado, Denver
Active, not recruiting - verified January 2009
Condition: Prostate Cancer
Intervention: Drug: degarelix
Sponsor: Ferring Pharmaceuticals
Active, not recruiting - verified February 2010
Condition: Prostate Cancer
Interventions: Drug: ridaforolimus (MK8669); Drug: Comparator: Placebo; Drug: open-label ridaforolimus (MK8669)
Sponsors: Merck; Ariad Pharmaceuticals
Recruiting - verified March 2010
Condition: Prostate Cancer
Intervention: Procedure: focal cryotherapy
Sponsor: Memorial Sloan-Kettering Cancer Center
Recruiting - verified March 2010
Condition: Recurrent Prostate Cancer
Intervention: Device: High Intensity Focused Ultrasound
Sponsor: USHIFU, LLC
Recruiting - verified March 2010
Conditions: Cancer; Castrate-Resistant Prostate Cancer; Mestastatic Prostate Cancer; Prostate Cancer
Interventions: Drug: AMG 102; Drug: AMG 102
Sponsor: Amgen
Active, not recruiting - verified March 2010
Condition: Prostate Cancer
Interventions: Device: HIFU (Sonablate® 500); Device: Brachytherapy
Sponsor: USHIFU, LLC
Recruiting - verified March 2010
Condition: Prostate Cancer
Intervention: Drug: IMC-A12 in combination with androgen deprivation therapy
Sponsors: Fred Hutchinson Cancer Research Center; ImClone LLC
Recruiting - verified February 2010
Condition: Prostatic Neoplasms
Intervention:
Sponsors: University of Washington; Canary Foundation; Early Detection Research Network
Recruiting - verified February 2010
Conditions: Non-Small Cell Lung; Breast Cancer; Melanoma; Upper GI Tract Carcinoma; Colon Carcinoma; Renal Cell Carcinoma; Bladder Carcinoma; Prostate Cancer
Interventions: Biological: V935; Biological: V934 EP (3 doses) and V935 (2 doses); Biological: V934 EP (5 doses) + V935 (2 doses); Biological: V934 DNA EP (3 doses)
Sponsor: Merck
Active, not recruiting - verified February 2010
Conditions: Prostate Cancer; Ovarian Cancer
Interventions: Drug: Sagopilone 16 mg/m2 i.v., Acetyl-L-Carnitine (ALC) 1000 mg tid, HRPC only: Prednisone or Prednisolone 5 mg bid; Drug: Sagopilone 16 mg/m2 i.v. and placebo 1000 mg tid, HRPC only: Prednisone or Prednisolone 5 mg bid
Sponsor: Bayer
Active, not recruiting - verified February 2010
Conditions: Solid Tumors; Ovarian Neoplasms; Prostate Cancer
Interventions: Drug: Comparator: MK4827 (PARP inhibitor); Drug: Comparator: MK4827 (PARP Inhibitor)
Sponsor: Merck
Recruiting - verified March 2010
Conditions: Prostate Cancer; Metastases; Pharmacokinetics
Intervention: Drug: Radium-223 chloride (Alpharadin™ )
Sponsor: Algeta ASA
Active, not recruiting - verified February 2010
Condition: Prostatic Neoplasms
Interventions: Drug: placebo + docetaxel/prednisone; Drug: dasatinib + docetaxel/prednisone
Sponsor: Bristol-Myers Squibb
Recruiting - verified October 2009
Condition: Prostate Cancer
Interventions: Biological: Sipuleucel-T; Biological: Sipuleucel-T; Biological: Sipuleucel-T
Sponsor: Dendreon
Recruiting - verified February 2010
Conditions: Breast Cancer; Colorectal Cancer; Head and Neck Cancer; Lung Cancer; Malignant Mesothelioma; Pancreatic Cancer; Prostate Cancer; Sarcoma
Interventions: Drug: cisplatin; Drug: pemetrexed disodium; Drug: sorafenib tosylate
Sponsors: Masonic Cancer Center, University of Minnesota; National Cancer Institute (NCI)
Recruiting - verified March 2010
Condition: Prostate Cancer
Interventions: Drug: vandetanib; Drug: Placebo
Sponsors: AstraZeneca; Canadian Urology Research Consortium
Terminated - verified February 2010
Condition: METASTATIC Castration Resistant PROSTATE CANCER (CRPC)
Intervention: Drug: Hamsa-1(TL-112)
Sponsor: Tiltan Pharma Ltd.
Recruiting - verified February 2010
Condition: Prostate Cancer
Interventions: Biological: IMC-A12; Drug: Mitoxantrone; Drug: Prednisone; Biological: IMC-1121B
Sponsor: ImClone LLC
Active, not recruiting - verified February 2010
Condition: Prostatic Neoplasms
Interventions: Drug: Prednisone; Drug: sunitinib; Drug: Placebo; Drug: Prednisone
Sponsor: Pfizer
Recruiting - verified March 2010
Condition: Prostate Cancer
Interventions: Radiation: Conventional Fractionated Intensity Modulated Radiotherapy; Radiation: Hypofractionated Intensity Modulated Radiotherapy
Sponsor: M.D. Anderson Cancer Center
Active, not recruiting - verified February 2010
Condition: Prostate Cancer
Intervention: Drug: BMS-641988 (AR#2)
Sponsor: Bristol-Myers Squibb
Completed - verified May 2009
Condition: Prostate Cancer
Interventions: Drug: docetaxel; Drug: LY2181308 sodium; Drug: Prednisone
Sponsor: Eli Lilly and Company
Recruiting - verified February 2010
Condition: Prostate Cancer
Interventions: Other: questionnaire administration; Procedure: quality-of-life assessment; Radiation: stereotactic radiosurgery
Sponsors: Case Comprehensive Cancer Center; National Cancer Institute (NCI)
Recruiting - verified March 2010
Condition: Prostate Cancer
Interventions: Dietary Supplement: Prevastein HC®; Other: Placebo
Sponsors: H. Lee Moffitt Cancer Center and Research Institute; Cognis
Completed - verified February 2010
Condition: Prostate Cancer
Interventions: Drug: Docetaxel; Drug: ZD4054
Sponsor: AstraZeneca
Recruiting - verified February 2010
Condition: Prostate Cancer
Interventions: Drug: ZD4054; Drug: Luteinising hormone-releasing hormone analogue (LHRHa); Drug: Megace; Drug: Estradiol; Drug: Prednisolone; Drug: Ketoconazole; Drug: Docetaxel
Sponsor: AstraZeneca
Recruiting - verified February 2010
Condition: Prostate Cancer
Intervention: Drug: Docetaxel plus prednisone
Sponsors: University of California, Irvine; Sanofi-Aventis
Active, not recruiting - verified March 2010
Condition: Advanced Solid Tumors
Intervention: Drug: BMS-777607
Sponsor: Bristol-Myers Squibb
Completed - verified August 2009
Condition: Prostatic Hyperplasia
Interventions: Drug: Polyphenon E, 200 mg EGCG bid; Drug: placebo
Sponsors: H. Lee Moffitt Cancer Center and Research Institute; National Cancer Institute (NCI)
Recruiting - verified February 2010
Condition: Adenocarcinoma of the Prostate
Intervention: Other: Single Photon Emission Computed Tomography (SPECT)
Sponsor: Washington University School of Medicine
Completed - verified February 2010
Conditions: Prostate Cancer; MRI
Intervention: Other: Magnetic Resonance Imaging; Spectroscopic Imaging, Contrast Enhanced Imaging
Sponsor: Memorial Sloan-Kettering Cancer Center
Recruiting - verified February 2010
Condition: Hormone Refractory Prostate Cancer
Intervention: Biological: ADENOVIRUS/PSA VACCINE
Sponsors: University of Iowa; Department of Defense
Recruiting - verified March 2010
Condition: Recurrent Prostate Cancer
Intervention: Biological: Adenovirus/PSA Vaccine
Sponsors: University of Iowa; Department of Defense
Recruiting - verified March 2010
Condition: Prostate Cancer
Intervention: Drug: RAD001, Docetaxel, Bevacizumab
Sponsors: USC/Norris Comprehensive Cancer Center; Novartis; Genentech; University of Southern California
Recruiting - verified March 2010
Condition: Prostate Cancer
Intervention: Device: Sonablate 500 (SB-500)
Sponsor: USHIFU, LLC
Not yet recruiting - verified March 2010
Condition: Hormone-Refractory Prostate Cancer
Intervention: Drug: Dasatinib
Sponsors: University of California, Irvine; Bristol-Myers Squibb
Recruiting - verified March 2010
Condition: Prostate Cancer
Interventions: Drug: bicalutamide; Drug: flutamide; Radiation: radiation therapy
Sponsors: Radiation Therapy Oncology Group; National Cancer Institute (NCI); Cancer and Leukemia Group B
Recruiting - verified March 2010
Condition: Prostatic Neoplasms
Intervention: Drug: TAK-700
Sponsor: Millennium Pharmaceuticals, Inc.
Recruiting - verified March 2010
Condition: Prostate Cancer
Intervention: Behavioral: Questionnaire
Sponsor: M.D. Anderson Cancer Center
Recruiting - verified March 2010
Condition: Prostate Cancer
Interventions: Drug: ABR-215050, tasquinimod; Drug: Placebo
Sponsor: Active Biotech Research
Active, not recruiting - verified March 2010
Condition: Prostate Cancer After a Radical Treatment
Interventions: Drug: Avodart; Other: placebo
Sponsor: GlaxoSmithKline
Active, not recruiting - verified February 2010
Condition: Prostate Cancer
Interventions: Radiation: 3-dimensional conformal radiation therapy; Radiation: intensity-modulated radiation therapy; Radiation: samarium Sm 153 lexidronam pentasodium
Sponsors: Radiation Therapy Oncology Group; National Cancer Institute (NCI)
Recruiting - verified February 2010
Condition: Suspicion of, or Known Breast Cancer
Intervention: Other: Radiology/MRI scan
Sponsor: Memorial Sloan-Kettering Cancer Center
Recruiting - verified February 2010
Conditions: Prostate Cancer; Breast Cancer; Ovarian Cancer; Lung Cancer; Gastric Cancer
Intervention: Drug: Docetaxel plus lonafarnib
Sponsor: Schering-Plough
Recruiting - verified March 2010
Condition: Prostate Cancer
Intervention: Drug: 117Lu-J591
Sponsor: Weill Medical College of Cornell University
Recruiting - verified March 2010
Condition: Prostate Cancer
Interventions: Drug: Placebo, docetaxel, prednisone; Biological: CNTO 95, docetaxel, prednisone
Sponsor: Centocor, Inc.
Completed - verified February 2010
Condition: Cancer
Interventions: Drug: fentanyl sublingual spray; Other: questionnaire administration
Sponsor: Insys Therapeutics Inc
Recruiting - verified October 2008
Condition: Prostate Cancer
Interventions: Drug: bicalutamide; Drug: docetaxel; Drug: flutamide; Drug: goserelin; Drug: leuprolide acetate; Procedure: adjuvant therapy; Radiation: 3-dimensional conformal radiation therapy; Radiation: intensity-modulated radiation therapy
Sponsors: Radiation Therapy Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Condition: Prostate Cancer
Interventions: Procedure: Brachytherapy; Behavioral: Questionnaire
Sponsor: M.D. Anderson Cancer Center
Recruiting - verified March 2010
Condition: Adenocarcinoma of the Prostate
Intervention: Drug: IMC-A12
Sponsor: ImClone LLC
Active, not recruiting - verified February 2010
Conditions: Prostatic Neoplasms; Neoplasm Metastasis
Interventions: Drug: Aflibercept (AVE0005); Drug: Placebo
Sponsors: Sanofi-Aventis; Regeneron Pharmaceuticals
Active, not recruiting - verified February 2010
Condition: Prostate Cancer
Interventions: Drug: dutasteride; Other: placebo
Sponsors: Fred Hutchinson Cancer Research Center; National Cancer Institute (NCI)
Recruiting - verified August 2009
Condition: Prostate Cancer
Interventions: Behavioral: CHESS System; Behavioral: Cancer Information Mentor
Sponsors: M.D. Anderson Cancer Center; National Cancer Institute (NCI)
Active, not recruiting - verified February 2010
Condition: Prostate Cancer
Interventions: Drug: Docetaxel; Drug: Carboplatin
Sponsor: M.D. Anderson Cancer Center
Recruiting - verified March 2010
Condition: Prostate Cancer
Interventions: Other: active surveillance; Procedure: conventional surgery; Procedure: quality-of-life assessment; Radiation: brachytherapy; Radiation: radiation therapy
Sponsors: NCIC Clinical Trials Group; National Cancer Institute (NCI); Cancer and Leukemia Group B; Eastern Cooperative Oncology Group; Southwest Oncology Group
Recruiting - verified March 2010
Condition: Prostate Cancer
Interventions: Drug: Docetaxel; Drug: Imatinib Mesylate; Drug: Leuprolide; Drug: Goserelin Acetate
Sponsors: M.D. Anderson Cancer Center; Novartis Pharmaceuticals
Completed - verified March 2010
Condition: Prostate Cancer
Interventions: Biological: bevacizumab; Drug: satraplatin
Sponsors: Barbara Ann Karmanos Cancer Institute; National Cancer Institute (NCI)
Active, not recruiting - verified February 2010
Condition: Hormone Refractory Prostate Cancer
Intervention: Drug: ABI-008
Sponsor: Abraxis BioScience Inc.
Active, not recruiting - verified June 2009
Conditions: Bladder Cancer; Breast Cancer; Kidney Cancer; Lung Cancer; Ovarian Cancer; Prostate Cancer; Unspecified Adult Solid Tumor, Protocol Specific
Interventions: Drug: custirsen sodium; Drug: docetaxel; Other: pharmacological study
Sponsor: NCIC Clinical Trials Group
Completed - verified March 2010
Condition: Neoplasms
Interventions: Drug: OGX-427; Drug: Docetaxel
Sponsor: OncoGenex Technologies
Recruiting - verified February 2010
Condition: Prostate Cancer
Interventions: Drug: enzastaurin; Drug: placebo; Drug: docetaxel; Drug: prednisone
Sponsor: Eli Lilly and Company
Active, not recruiting - verified February 2010
Condition: Prostate Cancer
Intervention: Procedure: 3T Magnetic Resonance Spectroscopic Imaging
Sponsor: M.D. Anderson Cancer Center
Recruiting - verified March 2010
Conditions: Breast Cancer; Cervical Cancer; Prostate Cancer; Colorectal Cancer; Lung Cancer
Interventions: Behavioral: Questionnaire; Behavioral: Patient Navigator (PN)
Sponsors: M.D. Anderson Cancer Center; Centers for Medicare and Medicaid Services
Recruiting - verified March 2010
Condition: Prostate Cancer
Intervention: Drug: Degarelix
Sponsor: Ferring Pharmaceuticals
Active, not recruiting - verified March 2010
Condition: Prostate Cancer
Intervention: Procedure: MRI Targeted Focal Thermal Therapy of Prostate Cancer
Sponsor: University Health Network, Toronto
Active, not recruiting - verified December 2006
Condition: Metastatic Prostate Cancer
Intervention: Drug: Dasatinib + Docetaxel
Sponsor: Bristol-Myers Squibb
Active, not recruiting - verified January 2009
Condition: Prostate Cancer
Interventions: Drug: cediranib maleate; Drug: prednisone; Genetic: gene expression analysis; Genetic: mutation analysis; Other: laboratory biomarker analysis; Other: pharmacological study; Procedure: dynamic contrast-enhanced magnetic resonance imaging
Sponsor: National Cancer Institute (NCI)
Active, not recruiting - verified June 2009
Condition: Bone Neoplasms
Intervention: Drug: Zoledronic acid
Sponsor: Novartis Pharmaceuticals
Active, not recruiting - verified February 2010
Condition: Prostate Cancer
Interventions: Drug: docetaxel; Drug: goserelin; Drug: leuprolide acetate; Procedure: conventional surgery
Sponsors: Cancer and Leukemia Group B; National Cancer Institute (NCI); Eastern Cooperative Oncology Group; NCIC Clinical Trials Group
Recruiting - verified March 2010
Condition: Prostate Cancer
Interventions: Procedure: AIR-MRSI; Procedure: PFC-MRSI
Sponsor: M.D. Anderson Cancer Center
Recruiting - verified March 2010
Condition: Prostate Cancer
Intervention: Drug: enzastaurin
Sponsor: Eli Lilly and Company
Active, not recruiting - verified February 2010
Conditions: Neoplasms; Prostatic Neoplasms
Interventions: Drug: cabazitaxel (XRP6258) (RPR116258); Drug: mitoxantrone; Drug: prednisone
Sponsor: Sanofi-Aventis
Completed - verified March 2010
Condition: Prostate Cancer
Interventions: Other: internet-based intervention; Procedure: assessment of therapy complications
Sponsors: Cancer and Leukemia Group B; National Cancer Institute (NCI)
Recruiting - verified March 2010
Condition: Metastatic Prostate Cancer
Interventions: Drug: docetaxel; Drug: zoledronic acid
Sponsor: National Cancer Institute, Naples
Completed - verified February 2010
Conditions: Primary Disease; Prostate Cancer
Intervention: Drug: sorafenib (200 or 400mg bid) and taxotere iv
Sponsor: Cliniques universitaires Saint-Luc- Université Catholique de Louvain
Active, not recruiting - verified March 2010
Conditions: Metastatic Cancer; Prostate Cancer
Interventions: Drug: antiandrogen therapy; Drug: docetaxel; Procedure: positron emission tomography; Procedure: radionuclide imaging; Radiation: carbon-11 acetate; Radiation: fludeoxyglucose F 18
Sponsor: Fred Hutchinson Cancer Research Center
Recruiting - verified March 2010
Condition: Prostate Cancer
Intervention: Drug: dasatinib
Sponsor: Bristol-Myers Squibb
Active, not recruiting - verified January 2009
Conditions: Colorectal Neoplasms; Melanoma; Prostatic Neoplasms; Renal Cell Carcinoma; Neoplasms
Intervention: Drug: CP-675,206
Sponsor: Pfizer
Recruiting - verified February 2010
Conditions: Breast Cancer; Cognitive/Functional Effects; Lung Cancer; Metastatic Cancer; Prostate Cancer
Interventions: Radiation: radiation therapy; Radiation: stereotactic radiosurgery
Sponsors: North Central Cancer Treatment Group; National Cancer Institute (NCI); American College of Surgeons; Eastern Cooperative Oncology Group; Radiation Therapy Oncology Group
Recruiting - verified March 2010
Condition: Pain
Intervention: Drug: Zoledronic acid
Sponsor: Novartis Pharmaceuticals
Completed - verified March 2010
Conditions: Breast Cancer; Lung Cancer; Metastatic Cancer; Pain; Prostate Cancer
Interventions: Dietary Supplement: calcium carbonate; Dietary Supplement: calcium citrate; Dietary Supplement: calcium glucarate; Dietary Supplement: vitamin D; Drug: calcium gluconate; Drug: zoledronic acid; Radiation: samarium Sm 153 lexidronam pentasodium; Radiation: strontium chloride Sr 89
Sponsors: Radiation Therapy Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Condition: Prostate Cancer
Interventions: Drug: Dutasteride; Drug: Matching placebo
Sponsor: GlaxoSmithKline
Active, not recruiting - verified March 2010
Conditions: Hot Flashes; Prostate Cancer
Interventions: Dietary Supplement: soy isoflavones; Dietary Supplement: soy protein isolate; Drug: venlafaxine; Other: placebo
Sponsors: Wake Forest University; National Cancer Institute (NCI)
Recruiting - verified March 2010
Conditions: Prostate Cancer; Breast Cancer; Bone Metastasis
Intervention: Drug: Zoledronic Acid
Sponsor: Novartis Pharmaceuticals
Completed - verified February 2010
Condition: Bone Metastases in Subjects With Advanced Cancer or Multiple Myeloma
Interventions: Drug: Zoledronic Acid; Biological: Denosumab
Sponsor: Amgen
Active, not recruiting - verified March 2010
Condition: Prostate Cancer
Interventions: Drug: LHRH Agonist; Drug: Sunitinib Malate; Procedure: Radical Prostatectomy
Sponsors: M.D. Anderson Cancer Center; Pfizer
Recruiting - verified March 2010
Condition: Prostate Cancer
Interventions: Drug: Docetaxel; Drug: Prednisone; Drug: OGX-011
Sponsor: OncoGenex Technologies
Active, not recruiting - verified June 2009
Condition: Prostate Cancer
Intervention: Drug: AR Antagonist (BMS-641988)
Sponsor: Bristol-Myers Squibb
Completed - verified July 2009
Condition: Bone Metastases in Men With Hormone-Refractory Prostate Cancer
Interventions: Drug: denosumab; Drug: zoledronic acid
Sponsor: Amgen
Active, not recruiting - verified March 2010
Condition: Prostate Cancer
Interventions: Drug: ZD4054; Drug: Docetaxel; Drug: Placebo
Sponsor: AstraZeneca
Completed - verified March 2010
Condition: Prostatic Neoplasms
Interventions: Drug: CP-751,871; Drug: docetaxel; Drug: prednisone; Drug: docetaxel; Drug: prednisone
Sponsor: Pfizer
Active, not recruiting - verified March 2010
Conditions: Prostate Cancer; Pancreatic Cancer; Non-Small-Cell Lung Cancer
Intervention: Drug: Nadroparin
Sponsor: GlaxoSmithKline
Completed - verified February 2010
Condition: Prostate Cancer
Interventions: Drug: antiandrogen therapy; Drug: docetaxel
Sponsors: Eastern Cooperative Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Condition: Prostate Cancer
Interventions: Procedure: 7800 cGy/39 fractions in 8 weeks; Procedure: 6000 cGy/20 fractions in 4 weeks
Sponsors: Ontario Clinical Oncology Group (OCOG); Canadian Institutes of Health Research (CIHR); Trans-Tasman Radiation Oncology Group (TROG)
Recruiting - verified February 2010
Condition: Prostate Cancer
Intervention: Device: Integrated Imaging High Intensity Focused Ultrasound
Sponsor: EDAP TMS S.A.
Recruiting - verified February 2010
Condition: Hormone Refractory Prostate Cancer
Interventions: Biological: denosumab; Biological: Placebo
Sponsor: Amgen
Active, not recruiting - verified March 2010
Condition: Prostate Cancer
Interventions: Drug: celecoxib; Drug: docetaxel; Drug: prednisolone; Drug: releasing hormone agonist therapy; Drug: zoledronic acid; Procedure: orchiectomy
Sponsor: Medical Research Council
Recruiting - verified March 2008
Condition: Prostate Cancer
Interventions: Drug: custirsen sodium; Drug: docetaxel; Drug: prednisone
Sponsor: NCIC Clinical Trials Group
Active, not recruiting - verified March 2010
Conditions: Cervical Cancer; Diarrhea; Prostate Cancer; Radiation Toxicity; Sarcoma
Interventions: Dietary Supplement: dietary intervention; Procedure: management of therapy complications; Procedure: quality-of-life assessment
Sponsors: Case Comprehensive Cancer Center; National Cancer Institute (NCI)
Active, not recruiting - verified March 2010
Condition: Prostate Cancer
Intervention: Biological: therapeutic estradiol
Sponsors: University of Medicine and Dentistry New Jersey; National Cancer Institute (NCI)
Completed - verified March 2010
Condition: Adenocarcinoma of the Prostate
Interventions: Procedure: high dose-rate brachytherapy; Procedure: intensity-modulated radiation therapy
Sponsor: Virginia Commonwealth University
Active, not recruiting - verified February 2010
Condition: Prostate Cancer
Intervention: Drug: Zoledronic acid
Sponsor: Novartis Pharmaceuticals
Completed - verified March 2010
Condition: Prostate Cancer
Intervention: Drug: fulvestrant
Sponsor: Roswell Park Cancer Institute
Completed - verified February 2010
Condition: Prostate Cancer
Intervention: Drug: 177Lu Radiolabeled Monoclonal Antibody HuJ591 (177Lu -J591)
Sponsor: Weill Medical College of Cornell University
Recruiting - verified March 2010
Condition: Prostate Cancer
Intervention: Radiation: radiotherapy
Sponsors: University of Wisconsin, Madison; National Cancer Institute (NCI)
Active, not recruiting - verified March 2010
Condition: Prostate Cancer
Intervention:
Sponsors: Maastricht Radiation Oncology; Maastricht University Medical Center
Withdrawn - verified March 2010
Condition: Urinary Incontinence
Interventions: Behavioral: Behavioral Therapy; Device: Pelvic Floor Electrical Stimulation; Behavioral: Biofeedback; Behavioral: Self Monitoring with Bladder Diaries
Sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Completed - verified March 2010
Condition: Prostatic Neoplasms
Interventions: Drug: Docetaxel; Drug: Prednisone; Drug: SU011248
Sponsor: Pfizer
Active, not recruiting - verified March 2010
Condition: Prostate Cancer
Intervention: Drug: PTK787/ZK 222584
Sponsors: University of Michigan; Novartis
Completed - verified January 2007
Conditions: Metastatic Cancer; Prostate Cancer
Interventions: Drug: atrasentan hydrochloride; Drug: docetaxel; Drug: prednisone; Other: placebo
Sponsors: Southwest Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Condition: Prostate Cancer
Intervention: Drug: sorafenib tosylate
Sponsors: NCIC Clinical Trials Group; National Cancer Institute (NCI)
Active, not recruiting - verified March 2010
Condition: Prostate Cancer
Interventions: Radiation: brachytherapy; Radiation: radiation therapy
Sponsors: Radiation Therapy Oncology Group; National Cancer Institute (NCI)
Active, not recruiting - verified May 2006
Condition: Prostate Cancer
Interventions: Drug: ZD4054; Drug: Placebo
Sponsor: AstraZeneca
Completed - verified February 2010
Condition: Prostate Cancer
Interventions: Procedure: computed tomography; Procedure: ultrasound imaging
Sponsors: Fox Chase Cancer Center; National Cancer Institute (NCI)
Completed - verified February 2010
Conditions: Metastatic Cancer; Prostate Cancer
Interventions: Drug: zoledronic acid; Other: placebo
Sponsors: Cancer and Leukemia Group B; National Cancer Institute (NCI); Southwest Oncology Group; Eastern Cooperative Oncology Group; NCIC Clinical Trials Group
Recruiting - verified March 2010
Condition: Prostate Cancer
Interventions: Radiation: iodine I 125; Radiation: palladium Pd 103; Radiation: radiation therapy
Sponsors: Radiation Therapy Oncology Group; National Cancer Institute (NCI)
Recruiting - verified March 2010
Conditions: Precancerous/Nonmalignant Condition; Prostate Cancer
Interventions: Dietary Supplement: selenium; Dietary Supplement: soy protein isolate; Dietary Supplement: vitamin E
Sponsor: NCIC Clinical Trials Group
Completed - verified March 2010
Condition: Prostate Cancer
Intervention: Radiation: radiation therapy
Sponsors: Fox Chase Cancer Center; National Cancer Institute (NCI)
Active, not recruiting - verified February 2010
Condition: Prostate Cancer
Interventions: Drug: Mitoxantrone (Novantrone); Drug: Bortezomib (PS-341)
Sponsors: M.D. Anderson Cancer Center; Millennium Pharmaceuticals, Inc.
Active, not recruiting - verified February 2010
Conditions: Prostatic Neoplasms; Metastases, Neoplasm
Intervention: Drug: ZD4054
Sponsor: AstraZeneca
Completed - verified February 2010
Condition: Prostate Cancer
Interventions: Drug: buserelin; Drug: custirsen sodium; Drug: flutamide; Procedure: conventional surgery; Procedure: neoadjuvant therapy
Sponsor: NCIC Clinical Trials Group
Completed - verified March 2010
Condition: Prostate Cancer
Intervention: Drug: MDX-010 / MDX-010 + Docetaxel
Sponsor: Bristol-Myers Squibb
Completed - verified March 2010
Conditions: Prostate Cancer; Osteoporosis; Hypogonadism
Intervention: Drug: alendronate
Sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Completed - verified March 2010
Conditions: Osteoporosis; Prostate Cancer
Interventions: Dietary Supplement: calcium carbonate; Dietary Supplement: cholecalciferol; Drug: conjugated estrogens; Drug: risedronate sodium
Sponsors: North Central Cancer Treatment Group; National Cancer Institute (NCI)
Completed - verified January 2007
Condition: Prostate Cancer
Intervention: Drug: gefitinib
Sponsor: NCIC Clinical Trials Group
Completed - verified March 2010
Condition: Prostate Cancer
Interventions: Drug: docetaxel; Drug: doxorubicin hydrochloride; Drug: estramustine phosphate sodium; Drug: ketoconazole; Drug: prednisone; Drug: vinblastine; Radiation: strontium chloride Sr 89
Sponsors: M.D. Anderson Cancer Center; National Cancer Institute (NCI)
Recruiting - verified February 2010
Condition: Multiple Myeloma and Plasma Cell Neoplasm
Interventions: Drug: prednisone; Drug: thalidomide
Sponsor: NCIC Clinical Trials Group
Completed - verified March 2010
Condition: Melanoma (Skin)
Intervention: Drug: alvocidib
Sponsor: NCIC Clinical Trials Group
Completed - verified March 2010
Condition: Sarcoma
Intervention: Drug: alvocidib
Sponsor: NCIC Clinical Trials Group
Completed - verified March 2010
Condition: Prostate Cancer
Interventions: Drug: bicalutamide; Drug: buserelin; Drug: cyproterone acetate; Drug: flutamide; Drug: goserelin; Drug: leuprolide acetate; Drug: nilutamide; Procedure: orchiectomy
Sponsors: NCIC Clinical Trials Group; National Cancer Institute (NCI); Southwest Oncology Group
Active, not recruiting - verified March 2010
Condition: Prostate Cancer
Interventions: Biological: luteinizing hormone-releasing factor; Radiation: radiation therapy
Sponsor: Medical Research Council
Active, not recruiting - verified July 2001
Conditions: Pain; Prostate Cancer; Quality of Life
Interventions: Drug: clodronate disodium; Drug: mitoxantrone hydrochloride; Drug: prednisone; Procedure: quality-of-life assessment
Sponsor: NCIC Clinical Trials Group
Completed - verified March 2010
Condition: Prostate Cancer
Intervention: Procedure: conventional surgery
Sponsors: Cancer and Leukemia Group B; National Cancer Institute (NCI); Southwest Oncology Group
Completed - verified March 2006
Condition: Prostate Cancer
Interventions: Drug: bicalutamide; Drug: buserelin; Drug: flutamide; Drug: goserelin; Drug: leuprolide acetate; Drug: nilutamide; Procedure: orchiectomy; Radiation: radiation therapy
Sponsors: NCIC Clinical Trials Group; National Cancer Institute (NCI); Eastern Cooperative Oncology Group; Cancer and Leukemia Group B; Southwest Oncology Group; Medical Research Council
Active, not recruiting - verified March 2010
Conditions: Colorectal Cancer; Lung Cancer; Ovarian Cancer; Prostate Cancer
Interventions: Other: screening questionnaire administration; Procedure: long-term screening
Sponsor: National Cancer Institute (NCI)
Active, not recruiting - verified February 2010
Condition: Ovarian Cancer
Intervention: Drug: ISIS 5132
Sponsor: NCIC Clinical Trials Group
Completed - verified March 2010
All Categories ... by Medical Condition » ... Cancers » ... Prostate Cancer 
Login/sign up for more tools for finding clinical trials. Login/Sign up Here
